3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
128
Colonic Neoplasms
54
Rectal Neoplasms
48
Carcinoma, Hepatocellular
29
Neoplasm Metastasis
23
Stomach Neoplasms
22
Neoplasms
11
Pancreatic Neoplasms
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Liver Neoplasms
6
Biliary Tract Neoplasms
5
Recurrence
4
Ovarian Neoplasms
4
Gastrointestinal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Unresectable Metastatic Colorectal Cancer
2
Peritoneal Neoplasms
2
Neoplastic Cells, Circulating
2
Intestinal Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Colorectal Cancer Metastatic
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
nilotinib
1
neratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease Progression
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts